Explore

FDA Warns Against Caffeine Vapes, Citing Lack of Safety Data and Unapproved Drug Status

FDA Warns Against Caffeine Vapes, Citing Lack of Safety Data and Unapproved Drug Status

The U.S. Food and Drug Administration (FDA) has issued warnings regarding caffeine vapes, classifying them as unapproved new drugs and raising significant safety concerns. These devices, often marketed as 'energy vapes' or 'diffusers,' heat a liquid containing caffeine and flavor into an aerosol for inhalation. Despite claims of being nicotine-free, the FDA highlights that there is almost no human research on their long-term safety. The agency has previously sent warning letters to manufacturers, stating that ingredients or impurities in inhaled products could trigger airway spasms and may be toxic to airway tissue. For instance, HELO caffeine vapes deliver approximately 1.3 mg of caffeine per 10 puffs, a significantly lower amount compared to a 12 oz cup of coffee, which contains 113 to 247 mg. The FDA emphasizes that no caffeine vape products are approved for medical use or for preventing or treating any condition, and their contents remain largely unknown and unregulated.

RFK Jr. Emphasizes Soil Health's Role in Human Well-being During North Dakota Visit

RFK Jr. Emphasizes Soil Health's Role in Human Well-being During North Dakota Visit

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. visited a ranch near Bismarck, North Dakota, to discuss the critical link between soil health and human health. During a roundtable on regenerative agriculture at the Black Leg Ranch, Secretary Kennedy highlighted how the vitality of soil directly impacts the human gut, which he stated influences overall health, emotions, moods, energy levels, and individual effectiveness. The event, held on November 5, 2026, included Senators John Hoeven and Kevin Cramer, both Republicans from North Dakota. Reporters were granted access for a limited 15-minute segment of the approximately 90-minute discussion, during which Secretary Kennedy elaborated on his views regarding the profound connection between agricultural practices and public health outcomes.

HHS Secretary Robert F. Kennedy Jr. Issues Interim Policy on Compounding Six Peptides

HHS Secretary Robert F. Kennedy Jr. Issues Interim Policy on Compounding Six Peptides

On October 28, 2026, the U.S. Department of Health and Human Services (HHS) published an interim Enforcement Discretion Policy regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Signed by HHS Secretary Robert F. Kennedy Jr., this policy outlines conditions under which HHS will not take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians who compound drug products using six specific peptide bulk drug substances. This interim measure is in effect while the official list of bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) is being developed through rulemaking. The policy aims to discourage the use of 'research use only' peptides from foreign manufacturers, offering a more controlled alternative for U.S. patients. Notably, this policy was issued by the HHS Office of the Secretary, rather than the FDA, despite FDA scientific reviewers having previously recommended against listing these pep...

Senate HELP Committee Proposes AI in Healthcare Act; CMS Finalizes New Organ Procurement Rules

Senate HELP Committee Proposes AI in Healthcare Act; CMS Finalizes New Organ Procurement Rules

Senator Bill Cassidy (R-LA), Chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee, has introduced a legislative discussion draft for the 'Protecting Americans Through Intelligent, Ethical, and Transparent (PATIENT) Artificial Intelligence in Health Care Act.' This proposal aims to direct the Department of Health and Human Services (HHS) to issue guidance on patient privacy in AI, clarify oversight responsibilities for AI-based technology between the Food and Drug Administration (FDA) and the Office of the National Coordinator for Health Information Technology (ONC), grant the FDA new review authority, and establish a payment pathway for AI tool adoption. Stakeholder feedback on this draft is due by December 1, 2026. Concurrently, the Centers for Medicare & Medicaid Services (CMS) has finalized new rules for Organ Procurement Organizations (OPOs) to enhance organ donation and strengthen accountability, including clearer requirements for OPO transitions, improved oversight of medical...

CMS Finalizes Rule for Medicare Drug Price Negotiation Program, Strengthening Drug Cost Controls

CMS Finalizes Rule for Medicare Drug Price Negotiation Program, Strengthening Drug Cost Controls

On November 5, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a final rule to codify policies for the Medicare Drug Price Negotiation Program, effective December 5, 2026. This rule establishes a permanent framework for negotiating prices of high-cost drugs, starting with prices applicable in 2029. The program aims to achieve greater value for beneficiaries and taxpayers while fostering innovation. The negotiation process involves engagement with primary manufacturers and interested parties, including patients, leading to an initial offer from CMS. Manufacturers can accept this offer or provide a counteroffer, followed by optional negotiation meetings and additional price exchange opportunities. The process concludes with a final offer from CMS. A significant new provision clarifies how CMS will identify qualifying single-source drugs, specifically addressing new formulations to prevent manufacturers from circumventing negotiation through minor product changes. This includes aggregating fix...

FDA Approves New Oral Pellet Formulation for Hereditary Angioedema Treatment

FDA Approves New Oral Pellet Formulation for Hereditary Angioedema Treatment

The U.S. Food and Drug Administration (FDA) has approved a new oral pellet formulation of Orladeyo (berotralstat) for adults and adolescents aged 12 and older who suffer from hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by sudden, unpredictable episodes of swelling in various parts of the body, including the skin, gut, and potentially life-threatening swelling in the airway. Orladeyo functions as a once-daily prophylactic oral therapy, working to block plasma kallikrein, which is responsible for the swelling in HAE. The original capsule formulation of Orladeyo received FDA approval in 2020. The new pellet formulation was initially approved for children aged 2 to 11 last December and is now extended to adolescents and adults, particularly benefiting those who experience difficulty swallowing capsules or prefer this alternative administration method. This development represents a strategic move in pharmaceutical lifecycle management, aiming to enhance patient convenience and adhe...

Midterm Elections Reveal Negative Public Sentiment Towards AI, Potentially Shaping Health AI Legislation

Midterm Elections Reveal Negative Public Sentiment Towards AI, Potentially Shaping Health AI Legislation

The recent U.S. midterm elections highlighted a negative public sentiment towards artificial intelligence, with voters rejecting data centers—essential for powering AI—on numerous ballot measures across several states. These results align with polling data indicating that many Americans believe AI causes more harm than good. This widespread public attitude raises questions about how it will influence future legislation and policy regarding AI use in health care. Key issues for lawmakers next year include state bills proposing 'sandboxes' for testing AI products and national legislation aimed at clarifying the Food and Drug Administration's (FDA) authority over AI, as well as reimbursement policies for AI-driven health technologies.

Wisconsin reports infant death linked to measles outbreak

Wisconsin reports infant death linked to measles outbreak

By Siddhi Mahatole Nov 5 (Reuters) - The Wisconsin Department of Health Services said on Thursday that an infant had died in connection with the ongoing measles outbreak in the state.

U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. to Visit Bismarck for Discussions on Regenerative Agriculture with North Dakota Tri...

U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. to Visit Bismarck for Discussions on Regenerative Agriculture with North Dakota Tri...

U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. is scheduled to travel to Bismarck, North Dakota, today. During his visit, Secretary Kennedy will participate in both a press conference and a roundtable discussion. The announcement was made by U.S. Senator Kevin Cramer. According to Senator Cramer's office, a key focus of Secretary Kennedy's visit will be to meet with various North Dakota tribes. The discussions with these tribal communities are expected to center on the topic of regenerative agriculture. This visit highlights an engagement between a high-ranking federal official and local tribal groups on matters of agricultural practices and community well-being. The specific details of the press conference and roundtable agenda, beyond the general topic, were not immediately provided, but the emphasis on regenerative agriculture suggests a focus on sustainable practices and their potential benefits for tribal lands and communities.

FDA Approves Two Gene Therapies for Inherited Immune Disorders, Highlighting Access Challenges

FDA Approves Two Gene Therapies for Inherited Immune Disorders, Highlighting Access Challenges

Within the past year, the FDA has approved two gene therapies for inherited immune disorders: etuvetidigene autotemcel (etu-cel, Waskyra) for Wiskott-Aldrich syndrome (WAS) and Exagamglogene autotemcel (Casgevy) for sickle cell disease and transfusion-dependent β-thalassemia. Etu-cel, approved in December 2025, is for WAS patients aged 6 months and older who are eligible for hematopoietic stem cell transplantation but lack a suitable donor. Casgevy's eligibility was expanded in July 2026 to include patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia, lowering the previous age threshold. While these approvals offer new treatment options, experts at the 2026 American Society for Transplantation and Cellular Therapy Gene Therapy Summit emphasized ongoing challenges in manufacturing quality, long-term safety, and patient access. For instance, Casgevy's label requires lifelong malignancy surveillance and regular blood counts, highli...

Peptilogics Enrolls First International Patient in RETAIN Trial for Prosthetic Joint Infection Treatment

Peptilogics Enrolls First International Patient in RETAIN Trial for Prosthetic Joint Infection Treatment

Peptilogics, a clinical-stage biotech company, has announced the enrollment of the first international patient in the pivotal RETAIN Phase 2/3 trial for zaloganan (PLG0206), a drug candidate designed to treat prosthetic joint infection (PJI). This enrollment took place in the U.K. at Leeds Teaching Hospitals NHS Trust and NIHR Clinical Research Facility: Leeds, marking the first patient outside the U.S. to join the study. Zaloganan is an investigational antimicrobial peptide engineered to target biofilm, the primary driver of serious infections across various implanted medical devices. PJI affects approximately two percent of joint replacements, leading to significant complications and often requiring multiple surgeries. The RETAIN trial is a randomized, double-blind, placebo-controlled study aiming to enroll approximately 240 patients across 50 sites in the U.S., U.K., and Australia.

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline